The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Syneron Medical missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased, and GAAP earnings per share contracted to a loss.
Gross margins increased, operating margins shrank, and net margins dropped.
Syneron Medical booked revenue of $61.0 million. The three analysts polled by S&P Capital IQ foresaw sales of $62.5 million. GAAP sales were 14% higher than the prior-year quarter's $53.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.05. The one earnings estimate compiled by S&P Capital IQ predicted $0.04 per share on the same basis. GAAP EPS were -$0.14 for Q4 against $0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.3%, 80 basis points better than the prior-year quarter. Operating margin was -8.1%, 1,910 basis points worse than the prior-year quarter. Net margin was -7.9%, 2,360 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $57.2 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $256.0 million. The average EPS estimate is $0.52.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 743 members rating the stock outperform and 32 members rating it underperform. Among 242 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 237 give Syneron Medical a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is outperform, with an average price target of $18.50.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Syneron Medical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Syneron Medical to My Watchlist.